AIDS

Tsoukas, Christos M.

doi: N/Apmid: N/A

Direct HIV-specific CTL activity mediated by activated circulating PBMC was undetectable in six INHI individuals under conditions where it is frequently observed in HIV disease progressors. Despite the absence of cells activated for killing HIV-infected targets in the circulation of these individuals, they appeared able to control their HIV infection by maintaining normal levels of CD4 and CD8 cells and low viral load.

Le Fichoux, Yves

doi: N/Apmid: N/A

Our data stress the utility of the follow-up by Western blotting for an early diagnosis of VL, and therefore an early treatment, for HIV-positive patients living in endemic areas. They suggest that in a latent

Montaner, Julio S.G.

doi: N/Apmid: N/A

Our results demonstrate that the cost of making combination antiretroviral therapy available worldwide would be exceedingly high, especially in countries with limited financial resources.

de Groot, Ronald

doi: N/Apmid: N/A

High recovery rates of naive, memory and total CD4+ T cells can be achieved in children below 3 years of age. Changes in CD8 counts did not correlate with age. These results indicate that regeneration of CD4+ T cells during HAART may be a thymus-dependent process.

Pearce, Gillian

doi: N/Apmid: N/A

In terms of antiretroviral therapy naive subjects, treatment with 300 or 600 mg abacavir twice daily was statistically superior to a 100 mg twice daily dose at 4 weeks. Combinations therapy containing abacavir-zidovudine-lamivudine was a highly effective antiretroviral regimen, resulting in substantial reductions in plasma HIV-1 RNA which may be comparable to combinations containing protease inhibitors. Abacavir was generally tolerated.

Chastang, Claude

doi: N/Apmid: N/A

ATRA is well tolerated and effective enough in Kaposi's sarcoma patients to warrant further evaluation. © 1998 Lippincott Williams & Wilkins

Klugman, Keith

doi: N/Apmid: N/A

The burden of bacteraemia due to

Opravil, Milos

doi: N/Apmid: N/A

The observed ability of HAART during early asymptomatic HIV infection to initiate rapid reversal of disease-induced T-cell activation and maturation abnormalities, while preserving pretherapy levels of immune function, supports the concept that therapeutic advantage is to be gained by commencing early aggressive antiretroviral therapy.

Albrecht, Helmut

doi: N/Apmid: N/A

Sandström, Eric

doi: N/Apmid: N/A

The virological outcome after 1 year of HAART was strongly correlated to prior treatment history and baseline viral load, whereas CD4+ lymphocyte count,